BIND Therapeutics

BIND Therapeutics

BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
Founded
2006
Raised
$37.9M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$25,500,000
Venture capital (Series D) - 2012
RUSNANO
$12,400,000
Venture capital (Series C) - 2010
Endeavour Vision Flagship Ventures Polaris Partners +2
Team Size
50+
Employees
Xconomy

Pfizer Might Buy Bind Therapeutics From Bankruptcy for $20M

Health Legal
Xconomy

Bind Therapeutics Sheds Employees, Considers New Capital or Deals

Health Funding